Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study
Roger S. McIntyre(University of Toronto), Elizabeth Pappadopulos(Goethe University Frankfurt), Rita Prieto(Saint Louis University), Ahmed Shelbaya(Pfizer (United States)), Xīn Gào(Qingdao University), Yu‐Chen Yeh(Abt Global (United States)), Richard Chambers(Pfizer (United States)), Matthieu Boucher(Pfizer (Canada)), Patricia Schepman(Pfizer (United States))
Cited by 15
Related Papers
A longitudinal study on the mental health of general population during the COVID-19 epidemic in China
|Brain Behavior and Immunity|2020|2.7k
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
|Bipolar Disorders|2012|1.2k
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
|The Canadian Journal of Psychiatry|2016|1.1k